BioProtect Overview
BioProtect has developed a proprietary technology platform for biodegradable balloons. The technology is designed for a wide range of clinical applications, including spacing for radiation oncology protection, aesthetics, and general surgery. The company's first application in the commercialization stage is the BioProtect/ProSpace Balloon System, which acts as a spacer for the protection of healthy tissue in patients receiving radiotherapy for prostate cancer. The product is commercially available in Europe and is undergoing clinical studies in the United States prior to FDA approval. BioProtect has a robust product pipeline developed in consultation with physicians regarding radiotherapy spacing and other unmet clinical needs.
Cumulative Funding Raised Over Time ($)
Latest News
growth-positive
Israeli balloon implant co BioProtect raises $28m
Israeli balloon implant company BioProtect has completed a $28 million financing round led by MVM Partners, with participation from current investors. The funds will be used for US commercialization of the BioProtect Balloon Implant System, which recently received FDA clearance for rectal protection during radiation therapy for prostate cancer. The companys CEO, Itay Barnea, expressed his belief in the potential of their product to revolutionize rectal protection from radiation toxicity during prostate cancer radiation therapy.
InvestmentExpand
growth-positive
Is it time to reconsider PSA tests for Prostate Cancer? | CTech
The article discusses the debate surrounding prostate cancer screening and treatment. It highlights the importance of personalized, patient-centered approaches and the potential side effects of invasive treatments. The CEO of BioProtect, Itay Barnea, emphasizes the need for a comprehensive evaluation of each patients unique factors. The global market for prostate cancer therapeutics is predicted to exceed $24.9 billion by 2030, driven by increasing cases and technological advancements in oncology. BioProtect produces biodegradable balloons for safe radiation therapy.
CustomersInvestment
growth-positive
BioProtect Notes Completion of Patient Enrollment for its IDE Pivotal Study of the ProSpace™ Balloon Spacer
BioProtect Ltd. has successfully enrolled all planned patients in the ongoing IDE ProSpace™ trial for its ProSpace™ Balloon Spacer. The trial aims to assess the safety and efficacy of the device in prostate cancer patients undergoing radiotherapy. The company expressed gratitude for the completion of the enrollment phase despite the challenges posed by the COVID-19 pandemic. BioProtects vision is to provide safer and improved clinical outcomes for patients undergoing radiation therapy. Last year, the company raised $25 million in funding from a group of international investors. The ProSpace™ Balloon Spacer is BioProtects first commercially available product, designed to reduce the radiation dose delivered to the anterior rectum by spacing it away from the prostate.
Investment
growth-positive
Prostate cancer protection co BioProtect raises $25m
Israeli startup BioProtect has closed a $25 million Series D equity financing round to fund the clinical trial of its ProSpace balloon spacer for prostate cancer treatment. The spacer helps reduce radiation therapy risks by pushing the prostate away from the rectum. The funds will also be used for technology platform expansion. BioProtects future pipeline includes applications for cervical cancer radiation therapy, pancreas radiation, and general surgery. The company aims to complete the pivotal study, gain FDA approval, and accelerate development of the next indication to its platform. The financing will support radiation oncology providers in shortening treatment cycles without compromising safety and cancer control.
InvestmentExpand
growth-positive
Israeli spacer balloon co BioProtect raises $13m
BioProtect, an Israeli bio-absorbable polymer spacer balloons developer, has announced the initial closing of a $13 million Series D equity financing round. The funding will be used to finance the ongoing multicenter FDA clinical trial of BioProtects lead product, the ProSpace balloon spacer, which protects prostate cancer patients undergoing radiation therapy. The funds will also support the expansion of the technology platform. The financing round was led by the family office of Vincent Tchenguiz, with participation from Accelmed Ventures and KB Investments.
Investment
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $62.25M |
| Last funding | Undisclosed |
| Stage | D |
| Rounds | 10 |
| Investors | 19 |
Team Members
4
Employees: 51-200
Web & Social Links
| Website | bioprotect.com |
Locations
Tsor St 8, Kokhav Ya'ir Tzur Yigal, Israel
Photos & Videos
2 item(s)
